Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer’s Disease Spectrum

| February 1, 2017 | 0 Comments

by Philip D. Harvey, PhD; Stephanie Cosentino, PhD; Rosie Curiel, PhD; Terry E. Goldberg, PhD; Jeffrey Kaye, MD; David Loewenstein, PhD; Daniel Marson, PhD, JD; David Salmon, PhD; Keith Wesnes, PhD; and Holly Posner, MD
Drs. Harvey, Curiel, and Loewenstein are with the University of Miami Leonard Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, Florida; Dr. Cosentino is with Columbia University College of Physicians and Surgeons, New York, New York; Dr. Goldberg is with North Shore Hofstra School of Medicine, Hempstead, New York; Dr. Kaye is with University of Alabama, Birmingham, Alabama; Dr. Marson is with University of Oregon, Portland, Oregon; Dr. Salmon is with USCD Medical Center, La Jolla, California; Dr. Wesnes is with Wesnes Cognition Ltd., Streatley on Thames, United Kingdom, and Department of Psychology, Northumbria University, Newcastle, United Kingdom; and Dr. Posner is with Global Product Development, Neuroscience & Pain, Pfizer, Inc., New York, New York.

Innov Clin Neurosci. 2017;14(1–2):30–39

Tags: , , , , ,

Category: Alzheimer's Disease, Cognition, Dementia, Drug Development, Evaluations, Neurology, Past Articles, Patient Assessment, Review, Scales, Trial Methodology

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.